Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints

Core Insights - Junshi Biosciences announced positive results from the Phase 3 clinical study of JS005, an anti-IL-17A monoclonal antibody for treating moderate to severe plaque psoriasis, meeting both co-primary and key secondary endpoints [1][3][4] Company Overview - Junshi Biosciences is an innovation-driven biopharmaceutical company founded in December 2012, focusing on the discovery, development, and commercialization of novel therapies [8] - The company has a diversified R&D pipeline with over 50 drug candidates across five therapeutic areas: cancer, autoimmune, metabolic, neurological, and infectious diseases [8] - Junshi has received approvals for five products in China and international markets, including toripalimab, the first domestically produced anti-PD-1 monoclonal antibody in China, approved in 40 countries [8] Clinical Study Details - The Phase 3 study of JS005 was conducted at 60 clinical sites across China, led by Professor Jianzhong Zhang, with the primary objective to assess the efficacy of JS005 compared to placebo [3][4] - Results indicated that JS005 significantly improved psoriasis lesions and achieved a higher proportion of participants with a sPGA score of 0 or 1 compared to placebo, demonstrating good safety [4][5] Disease Context - Psoriasis is a chronic inflammatory disease with a global prevalence of 2.0% to 3.0%, and 0.47% in China, affecting approximately 125 million patients worldwide [2] - Patients with moderate to severe psoriasis face increased risks of metabolic syndrome, cardiovascular disease, and mental health issues, highlighting the urgent need for effective treatments [2]